Trevi Therapeutics
Trevi Therapeutics develops Nalbuphine® ER for chronic pruritus (itch).
The Company has generated clinical proof of concept data in two important itch conditions: uremic pruritus and prurigo nodularis.and is starting phase IIb clinical studies
